IP Library Granted Patent US 10,350,237
Granted Patent B2
US 10,350,237 · App. 14/765,992 · Granted Jul 16, 2019

Conductive biomaterial for enhancement of conduction in vitro and in vivo

Inventor: Ren-Ke Li (Toronto, CA)
Assignee: University Health Network
A61K31/787A61K31/785A61K47/61A61K47/6435A61K47/6903A61L27/26A61L27/50A61L31/041A61L31/14C08G61/124A61K9/0024A61K47/36A61L2400/06A61L2430/20C08G2261/128C08G2261/3221
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,350,237
App. No.
14/765,992
Granted
Jul 16, 2019
Kind
B2
Abstract

A biocompatible, electrically conductive biomaterial capable of earn carrying the electrical potential of a cardiac impulse and comprising (1) a conductive polymer such as polyaniline, polypyrrole or polythiophene, and (ii) a biocompatible component such as a polysaccharide, a protein, or a polypeptide, in particular chitosan or gelatin, is described. The material can take the form of a hydrogel, membrane, sheet or mesh. It can be used to restore or improve electrical impulse propagation across damaged tissue or scar region of the myocardium, in particular in the ti treatment of myocardial infarction and arrhythmia.

Claims (16)

1. A biocompatible material for treating a heart comprising

a conductive polymer comprising a polypyrrole-based polymer; and

a biocompatible component comprising chitosan,

wherein the biocompatible material is prepared by:

mixing the conductive polymer and the biocompatible component in solution to form a copolymer solution;

neutralizing the pH of the copolymer solution; and

allowing the conductive polymer and the biocompatible component to crosslink to form a hydrogel in the presence of a cross-linking agent;

and wherein the biocompatible material is biocompatible with cardiac tissue.

2. The biocompatible material of claim 1 , wherein the conducting polymer has a bulk specific conductance of greater than or equal to about 10 −5 Siemens per centimeter.

3. The biocompatible material of claim 1 , wherein the biocompatible material is produced by further molding the hydrogel into a desired shape.

4. The biocompatible material of claim 1 wherein the crosslinking agent is gluteraldehyde, methylene-bis-acrylamide, diethylene glycol diacrylate, ethylene glycol diacrylate, triethylene glycol-bis-methacrylate, ethylene glycol-bis-methacrylate, ethylene glycol-dimethacrylate, bisacrylamide, triethyleneglycol-bis-acrylate, 3,3′-ethylidene-bis(N-vinyl-2-pyrrolidone), trimethylolpropate trimethacrylate, glycerol trimethacrylate, polyethylene glycol dimethacrylate, polyacrylate esters, polymethacrylate esters, genipin, or tannic acid.

5. The biocompatible material of claim 4 wherein the crosslinking agent is gluteraldehyde.

6. A method of treating a heart condition, the method comprising

introducing the biocompatible material of claim 1 to the heart, wherein the material includes a conductive polymer and a biocompatible component.

7. The method of claim 6 , wherein the heart condition is myocardial infarction, heart failure, atrioventricular block, arrhythmia or a conduction abnormality.

8. The method of claim 6 , wherein the conducting polymer has a bulk specific conductance of greater than or equal to about 10 −5 Siemens per centimeter.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 3, 2016
From: LI, REN-KE
To: UNIVERSITY HEALTH NETWORK
Reel/Frame 037654/0116 →
Continuity (2)
Provisional Application 61760858 · Feb 5, 2013
Related Publication 20150366900A1 · Dec 24, 2015